Lantheus Holdings heads into its August 6 earnings report with short sellers rebuilding positions and the stock nursing a 5% weekly loss — a setup that mirrors investor caution ahead of what has historically been a volatile print.
The short interest story is the dominant angle this week. Bears have added meaningfully to their position, with short interest climbing to 10.2% of the free float — a 9% rise on the week and 24% higher than a month ago. That steady accumulation has been running since late June, when SI was closer to 5.4 million shares versus today's 6.75 million. Despite that build, the borrow market remains relaxed. Availability at 391% means there are roughly four shares available to borrow for every one already borrowed — well into normal territory — and cost to borrow is holding at just 0.59%. Shorts can still get in cheaply and easily, which suggests the current accumulation reflects a fundamental view rather than a forced technical position. Options sentiment tells a similar story: the put/call ratio at 0.50 is actually slightly below its 20-day average, tracking nearly 1.4 standard deviations below normal, which means options traders are not bidding up downside protection ahead of results despite the share price weakness. The positioning looks deliberate rather than panicked.
The Street remains firmly in the bull camp, but the freshest analyst move cuts the other way. Mizuho trimmed its target from $120 to $115 on July 29 while holding its Outperform rating — a mild vote of caution immediately before the print. Truist lifted its target to $125 just two weeks ago, and B. Riley moved its target to $129 in early July. The consensus is still Buy, with a mean price target of $112.75 against a current price of $102.64, implying about 10% upside. The bull case rests on pipeline momentum: FDA approvals for PYLARIFY TruVu and tentative approval for PNT2003 represent tangible execution on the radiopharmaceutical roadmap. Bears counter with pricing pressure and intensifying oncology competition, with Alzheimer's diagnostics contributions still several years out. The EPS surprise factor score ranks in the 86th percentile, suggesting the company has consistently beaten estimates — context that matters heading into a report.
Earnings history is unusually clean here. The May 7 print produced an 8% one-day gain and extended to a 12% five-day move. That single data point is the only one available in the reaction history, so it should be treated carefully — but it does indicate the stock can move sharply on results, in either direction.
The institutional base remains stable. BlackRock holds 12.6% of shares. Fidelity added around 303,000 shares through late May, and American Century built a position of roughly 1 million shares as of end-June. That quiet accumulation sits in contrast to the short-side build, sharpening the bull-bear divide. The ORTEX short score has edged higher all week, reaching 61.9 — its highest reading of the past 10 days — reflecting the combination of rising SI and a weakening price trend.
The August 6 report now becomes the focal point: whether the shorts are right to be rebuilding into a name with a strong beats record, or whether the pipeline execution that drove the stock up over 60% year-to-date reasserts itself with another positive surprise.
See the live data behind this article on ORTEX.
Open LNTH on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
